Therapeutic | Golimumab |
Target | TNFA |
Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS |
Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK |
100% seqID Fv Structure | 5yoy [Fvs: GD, HE, IF, PM, QN, RO] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 5yoy [Fvs: GD, HE, IF, PM, QN, RO] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | Medarex UltiMAb Mouse |
INN Year Proposed | 2004 |
INN Year Recommended | 2005 |
Companies Involved | Centocor, Centocor Ortho Biotech, Janssen Biotech, Merck & Co, Mitsubishi Tanabe Pharma Corporation, Medarex |
Conditions Approved | Ankylosing spondylitis, Juvenile rheumatoid arthritis, Non-radiographic axial spondyloarthritis, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis |
Conditions Active | Hearing disorders, Type 1 diabetes mellitus |
Conditions Discontinued | Asthma, Cardiovascular disorders, Sarcoidosis, Uveitis |
Notes |